CAS: 538-24-9; Trilaurin

相似化合物

620-67-7 621-70-5 537-39-3

上下游产品

CAS号143-07-7 月桂酸 | CAS号56-81-5 甘油 | CAS号112-16-3 十二酰氯 | CAS号40738-26-9 單月桂酸甘油酯 | CAS号96-11-7 1,2,3-三溴丙烷 | CAS号22412-97-1 十二(烷)酸十四(烷)酯 | CAS号143-07-7 月桂酸 | CAS号56-81-5 甘油 | CAS号40738-26-9 單月桂酸甘油酯 | CAS号17598-94-6 1,2-二月桂酸酯 | CAS号111-82-0 月桂酸甲酯 | CAS号539-93-5 1,3-二月桂酸甘油酯 | CAS号1678-45-1 2-lauroylglycerol | CAS号120-40-1 N,N-二乙醇十二酰胺 | CAS号106-33-2 月桂酸乙酯

Alkaline Earth Salt Of/the/ Methylsulfuric Acid 反应生成 甘油三酯
参考文献:Othmer,Zeitschrift Für Anorganische Und Allgemeine Chemie,1915,Vol. 91,P. 240
标题:Othmer,Zeitschrift Für Anorganische Und Allgemeine Chemie,1915,Vol. 91,P. 240

专利信息

专利号:US-9018371-B2
优先权日:2007-03-07
标 题 :Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
发明人：JEONG LAK SHIN; KIM HEA OK; JACOBSON KENNETH A; CHOE SEUNG AH
权利人:JEONG LAK SHIN; KIM HEA OK; JACOBSON KENNETH A; CHOE SEUNG AH; FM THERAPEUTICS CO LTD; US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES THE OFFICE OF TECHNO
摘要:Disclosed are adenosine derivatives, methods for the synthesis thereof, and pharmaceutical compositions for the prevention and treatment of inflammatory diseases, comprising the same as an active ingredient. The adenosine derivatives have high binding affinity and selectivity for adenosine receptors, especially for A 3 adenosine receptors and act as A 3 adenosine receptor antagonists, and exhibit anti-inflammatory activity. Thus, the adenosine derivatives are useful in the prevention and treatment of inflammatory diseases.

专利号:US-7811612-B2
优先权日:2005-01-20
标 题 :Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis
发明人：KIM JUNG-KEUN; KIM SE-WON; KIM HYUNG-GUN; KO SEON-YLE; BAEK DONG-HEON; CHANG SUNHWA
权利人:OSCOTEC INC
摘要:The present invention relates to an extract of an herbal mixture of Notoginseng radix, Rehmanniae radix preparata and Acanthopanacis cortex , and a method for treating arthritis using the extract as an effective ingredient. The extract of the herbal mixture of the present invention can effectively inhibits the release of inflammatory substances and the synthesis of cartilage destroying substance as well as the progress of arthritis.

专利号:US-2013345116-A1
优先权日:2012-06-21
标题 :Composition Containing Trail for Prevention or Treatment of Metabolic Diseases
发明人：LEE HYE-JEONG
权利人:LEE HYE-JEONG
摘要:The present invention provides a pharmaceutical composition and a food composition containing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) as an active ingredient for prevention or treatment of metabolic diseases. The TRAIL according to the present invention can reduce blood glucose, neutral fat, cholesterol, and free fatty acid, and neutral fat in liver, and reduce the synthesis of fat, and promote the lipid metabolism, and thus can be effectively used for the prevention or treatment of metabolic diseases.

专利号:WO-2024058717-A1
优先权日:2022-09-14
标题:Engineering of rhizomucor miehei lipase towards amide bond formation for the synthesis of medium to long chain n-acyl glycines in aqueous media
发明人：LI ZHI; KUA KAI BIN; NGUYEN KIEN TRUC GIANG
权利人:WILMAR INTERNATIONAL LTD; NAT UNIV SINGAPORE
摘要:Described herein are lipase variants of a Rhizomucor Miehei Lipase. The lipase variants may be used to prepare medium to long chain N-acyl glcyines. The variants may have a parent sequence of SEQ ID NO: 3; and a D156 substitution and/or a L258 substitution, wherein the D156 substitution is selected from the group consisting of serine (S), glycine (G), glutamic acid (E), and threonine (T), wherein if the D156 substitution is glycine, the lipase variant comprises at least one other substitution, and the L258 substitution is selected from the group consisting of lysine (K), arginine (R), glutamine (Q), asparagine (N), histidine (H), and serine (S). The variants may have a parent sequence of SEQ ID NO: 3; and at least one substitution of the following amino acids: D156, L258. L267, V254, L255, N264, T265, S83, S84, W88, R30, R86, S56, L58, and 1I59.

专利号:US-9371387-B2
优先权日:2011-11-10
标题 :Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient
发明人：LEE BONG HEE; BYUN KYUNG HEE
权利人:UNIV GACHON IND ACAD COOP FOUND
摘要:Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.

专利号:US-10927101-B2
优先权日:2016-05-31
标 题 :Neopetrosides A and B, and synthesis method thereof
发明人：HAN JIN; JEONG SEUNG HUN; SONG IN-SUNG; KIM HYOUNG KYU; KIM NARI; SHUBINA LARISA K; MAKARIEVA TATYANA N; STONIK VALENTIN A; YASHUNSKY DMITRY V; NIFANTIEV NIKOLAY E
权利人:UNIV INJE IND ACAD COOP FOUND
摘要:The present invention relates to novel pyridine nucleoside compounds, Neopetroside A (NPS A) and Neopetroside B (NPS B) obtained by fractionating an extract of Neopetrosia sp. which is a marine sponge, with ethanol, into n-butanol (n-BuOH). When the NPS A was treated with myocardial cells, it activates oxidative phosphorylation, basal and mitochondrial respiration induced by ATP and ATP synthesis, and stimulates the glycolysis activity and when the NPS A was treated with an ischemic reperfusion injury model, the left ventricular pressure injured by ischemic reperfusion was recovered and the size of myocardial injury site was significantly reduced and as a result, can be provided as the pharmaceutical composition for preventing or treating ischemic heart disease or the health functional food for preventing or improving the same.